Two UB drug development and discovery projects have received investments from the Empire Discovery Institute.
Subscribe
One project focuses on an immunotherapy platform developed by UB pharmacy researcher Sathy Balu-Iyer and his team that could benefit patients who are receiving gene therapy for a variety of diseases. The other will seek to design a therapy for multiple sclerosis (MS) that leverages a novel drug target discovered by a team led by UB medical researcher M. Laura Feltri.
The institute will advance both efforts through its Medicines Discovery Award Program, a competitive incubator and accelerator program designed to identify and advance promising early-stage drug discovery into early proofs of concept. Successful projects will exit the program as either a licensing transaction to a strategic pharmaceutical partner or as an Empire Discovery Institute-created startup company.
BridgeBio Pharma, Inc. and UC Davis Establish Collaboration to Transform Research into Potential Therapies for Genetically Driven Diseases
April 13, 2021 07:42 ET | Source: BridgeBio Pharma, Inc. BridgeBio Pharma, Inc. Palo Alto, California, UNITED STATES
PALO ALTO, Calif. and SACRAMENTO, Calif., April 13, 2021 (GLOBE NEWSWIRE) BridgeBio Pharma, Inc. (NASDAQ: BBIO) today announced a collaboration with the University of California, Davis (UC Davis), to advance research and the development of investigational medicines for patients with genetically driven conditions and cancers.
“UC Davis is a top-tier research university and we feel honored to get the chance to collaborate closely with the talented team there as we work to discover, create, test and deliver breakthrough medicines for people who are suffering from genetic diseases,” said BridgeBio founder and CEO Neil Kumar, Ph.D.
BridgeBio Pharma, Inc Reports First Quarter 2021 Financial Results And Business Update streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Two UB drug development and discovery projects have received investments from the Empire Discovery Institute.
One project focuses on an immunotherapy platform developed by UB pharmacy researcher Sathy Balu-Iyer and his team that could benefit patients who are receiving gene therapy for a variety of diseases. The other will seek to design a therapy for multiple sclerosis (MS) that leverages a novel drug target discovered by a team led by UB medical researcher M. Laura Feltri.
The institute will advance both efforts through its Medicines Discovery Award Program, a competitive incubator and accelerator program designed to identify and advance promising early-stage drug discovery into early “proofs of concept.” Successful projects will exit the program as either a licensing transaction to a strategic pharmaceutical partner or as an Empire Discovery Institute-created startup company.
University at Buffalo
Teams will seek to develop treatment options that could benefit patients with multiple sclerosis, hemophilia and more
BUFFALO, N.Y. Two University at Buffalo drug development and discovery projects have received investments from the Empire Discovery Institute.
One project focuses on an immunotherapy platform developed by UB pharmacy researcher Sathy Balu-Iyer and his team that could benefit patients who are receiving gene therapy for a variety of diseases. The other will seek to design a therapy for multiple sclerosis (MS) that leverages a novel drug target discovered by a team led by UB medical researcher M. Laura Feltri.